Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm study of deferasirox in transfusion-dependent beta-thalassemia patients intolerant or unresponsive to prior chelation
IRCT2014122920051N1Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in beta thalassemia, sponsored by Novartis. Primary endpoints: Efficacy of deferasirox and Safety of deferasirox. Started Feb 2015; status: completed.
02
Drugs
deferasirox
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on IRCT2014122920051N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014122920051N1.